Menlo Therapeutics, Japan Tobacco, Torii deal

Menlo Therapeutics granted Japan Tobacco and its Torii subsidiary exclusive, Japanese rights to develop and commercialize serlopitant ( VPD-737). Japan Tobacco and Torii will co-develop the neurokinin 1 (NK1) substance P receptor (TACR1) antagonist, and Torii will commercialize the product. Menlo will receive an undisclosed upfront payment and is eligible for milestones and royalties. ...